...
首页> 外文期刊>Journal of Leukocyte Biology: An Official Publication of the Reticuloendothelial Society >A caveat for T cell transfer studies: generation of cytotoxic anti-Thy1.2 antibodies in Thy1.1 congenic mice given Thy1.2+ tumors or T cells
【24h】

A caveat for T cell transfer studies: generation of cytotoxic anti-Thy1.2 antibodies in Thy1.1 congenic mice given Thy1.2+ tumors or T cells

机译:T细胞转移研究的警告:给予Thy1.2 +肿瘤或T细胞的Thy1.1同系小鼠中产生细胞毒性抗Thy1.2抗体

获取原文
           

摘要

Thy1.1 congenic B6.PL mice were used to simultaneously monitor Thy1.2+ E.G7-OVA tumors transplanted in the a.c. of the eye and i.v.-transferred tumor-specific Thy1.2+ CTLs to determine mechanisms that inhibit the tumoricidal activity of CTL responses in mice with established ocular tumors. Transferred CTLs were systemically deleted in mice with established ocular tumors. However, this deletion was not a unique mechanism of immune evasion by ocular tumors. Rather, development of Thy1.2+ tumors in the eye or skin of B6.PL mice generated cytotoxic anti-Thy1.2 antibodies that eliminated a subsequent Thy1.2+ T cell transfer. Anti-Thy1.2 immune responses in B6.PL mice were influenced by the route of antigen administration, as the serum concentration of cytotoxic anti-Thy1.2 antibodies was 92-fold greater in mice with eye tumors in comparison with mice with skin tumors. In addition, anti-Thy1.2 immune responses were detected in B6.PL mice given na?ˉve Thy1.2+ T cells i.p. but not i.v. Anti-Thy1.2 responses were augmented in B6.PL mice with ocular Thy1.2+ EL-4 tumors that did not express OVA, suggesting immunodominance of OVA antigen over Thy1.2. Thy1.1+ T cells given i.p. was not immunogenic in Thy1.2 congenic mice. These data reaffirm that the introduction of antigens in the a.c. induces robust antibody responses. Experimentation using allotypic differences in Thy1 between donor cells and recipient mice must consider cytotoxic anti-Thy1 antibody generation in the interpretation of results.
机译:Thy1.1同基因B6.PL小鼠用于同时监测在a.c.中移植的Thy1.2 + E.G7-OVA肿瘤。通过眼部和静脉内转移的肿瘤特异性Thy1.2 + CTL来确定抑制具有确定的眼部肿瘤的小鼠中CTL反应的杀肿瘤活性的机制。在具有确定的眼肿瘤的小鼠中全身性地删除转移的CTL。然而,这种缺失不是眼肿瘤免疫逃避的独特机制。相反,B6.PL小鼠的眼睛或皮肤中Thy1.2 +肿瘤的发展产生了细胞毒性抗Thy1.2抗体,从而消除了随后的Thy1.2 + T细胞转移。 B6.PL小鼠的抗Thy1.2免疫反应受抗原施用途径的影响,因为眼部肿瘤小鼠的细胞毒性抗Thy1.2抗体的血清浓度是皮肤肿瘤小鼠的92倍。此外,在给初次应用Thy1.2 + T细胞的B6.PL小鼠中检测到抗Thy1.2免疫反应。但不是i.v.在不表达OVA的眼Thy1.2 + EL-4肿瘤的B6.PL小鼠中,抗Thy1.2反应增强,这表明OVA抗原相对于Thy1.2具有免疫优势。腹膜内给予Thy1.1 + T细胞在Thy1.2同系小鼠中没有免疫原性。这些数据证实了在AC中引入抗原。诱导强烈的抗体反应。使用供体细胞和受体小鼠之间Thy1的异型性差异进行的实验必须在解释结果时考虑细胞毒性抗Thy1抗体的产生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号